Legend Biotech Corp - ADR Aktie News

Terns Pharmaceuticals shares jumped as much as 50% on news that cancer cell counts fell over 99% in nearly three-fourths of leukemia patients treated with the firm's once-daily pill.

SOMERSET, N.J., Dec. 06, 2025 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, today announced new long-term clinical and translational data for CARVYKTI® (ciltacabtagene autoleucel; cilta-cel) from the CARTITUDE-1 and CARTITUDE-4 studies in relapsed / refractory multiple myeloma (RRMM) patients. In triple-class-exposed patients wh...

Following Legend Biotech's solid financial results for Q3, its average PT rose to $74.90, which implies an upside of about 171.2% from its current stock price. Thanks to increased demand for its "gem" called Carvykti, adjusted net loss decreased by 55.2% to $18.8 million in Q3. A key reason for its growing sales is its superior efficacy compared to Elrexfio, Abecma, and Tecvayli.

31,000-square-foot site expands Legend's U.S. R&D footprint and strengthens its position as a global leader in cell therapy innovation

Legend Biotech Corporation ( LEGN ) Q3 2025 Earnings Call November 12, 2025 8:00 AM EST Company Participants Jessie Yeung - Vice President of Finance, Investor & Public Relations Ying Huang - CEO & Director Alan Bash - President of CARVYKTI® Carlos Santos - Chief Financial Officer Guowei Fang - President of Research & Development Conference Call Participants Huidong Wang - Barclays Bank PLC, Re...

Two oral and seven poster presentations further support the CARVYKTI® research in multiple myeloma First-in-Human Phase 1 data for allogeneic CAR-T cell therapy for NHL to be featured in oral session SOMERSET, N.J., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, today announced that it will present two oral presenta...

SOMERSET, N.J., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, will host a conference call for investors at 8:00 am ET on Wednesday, November 12, 2025, to review third quarter 2025 results.

The U.S. Food and Drug Administration on Friday approved labeling changes for Johnson & Johnson and its partner Legend Biotech's blood cancer therapy to include a boxed warning for a potentially fatal gastrointestinal condition.